Use of angiotensin-converting enzyme inhibitors in patients with diabetes and coronary artery disease.
Dell'Italia
Louis J
LJ
Birmingham Veteran Affairs Medical Center, Department of Medicine, University of Alabama at Birmingham, USA.
Rocic
Petra
P
Lucchesi
Pamela A
PA
D000804:Angiotensin II / Q000096:biosynthesis; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use*; D000959:Antihypertensive Agents / Q000627:therapeutic use; D001920:Bradykinin / Q000378:metabolism; D053818:Chymases; D003324:Coronary Artery Disease / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D003925:Diabetic Angiopathies / Q000188:drug therapy* / Q000201:enzymology / Q000503:physiopathology; D004730:Endothelium, Vascular / Q000201:enzymology / Q000502:physiology*; D005342:Fibrinolysis / Q000502:physiology; D006801:Humans; D019808:Losartan / Q000627:therapeutic use; D018384:Oxidative Stress / Q000502:physiology; D012697:Serine Endopeptidases / Q000502:physiology
D000806:Angiotensin-Converting Enzyme Inhibitors; D000959:Antihypertensive Agents; D000804:Angiotensin II; D012697:Serine Endopeptidases; D053818:Chymases; D019808:Losartan; D001920:Bradykinin